We believe that real-time tracking of Gold Anchor fiducial markers creates unprecedented opportunities to provide safe and economical radiotherapy with high accuracy and precision.

A recent study of 132 prostate cancer patients, with Gold Anchor markers automatically detected on Varian TrueBeam, showed that:
– Across 2659 fractions, intrafraction motion correction was performed 582 times, in 463 fractions (17%);
– 77% of the patients had at least one shift during their treatment course; the median shift was 3.6 mm; and
– 36% of the patients had shifts with an average magnitude of at least 5 mm.

Read the abstract from The University of Chicago Comprehensive Cancer Center.